Abcellera Biologics Inc
ABCL5.576USD
+0.216+4.02%
Market hours （ET）Quotes delayed by 15 min
1.67BMarket Cap
LossP/E TTM
More Details of Abcellera Biologics Inc Company
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. The Company’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the antibody discovery problems. The Company has developed technology platforms to unlock drug classes, targets, and modalities, including transmembrane proteins, T-cell engagers, and peptide-MHCs. The Company is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two preclinical programs in its internal pipeline are ABCL575 and ABCL635. ABCL635 is an antibody-drug candidate against an undisclosed target with an indication in metabolic and endocrine conditions. ABCL575 targets OX40 ligand and is being developed as a therapy for the treatment of atopic dermatitis and other indications of autoimmunity and inflammation.
Abcellera Biologics Inc Info
Ticker SymbolABCL
Company nameAbcellera Biologics Inc
IPO dateDec 11, 2020
CEODr. Carl L.G. Hansen, Ph.D.
Number of employees596
Security typeOrdinary Share
Fiscal year-endDec 11
Address150 W 4Th Avenue
CityVANCOUVER
Stock exchangeNASDAQ Global Select Consolidated
CountryCanada
Postal codeV5Y 1G6
Phone16045599005
Websitehttps://www.abcellera.com/
Ticker SymbolABCL
IPO dateDec 11, 2020
CEODr. Carl L.G. Hansen, Ph.D.
Company Executives of Abcellera Biologics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
283.96K
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Andrew W. Lo, Ph.D.
Dr. Andrew W. Lo, Ph.D.
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Lead Independent Director
Lead Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
283.96K
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Andrew W. Lo, Ph.D.
Dr. Andrew W. Lo, Ph.D.
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2024Q2
FY2023Q2
By BusinessUSD
Name
Revenue
Proportion
Licensing revenue
10.45M
61.14%
Research fees
6.64M
38.86%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Licensing revenue
10.45M
61.14%
Research fees
6.64M
38.86%
Shareholding Stats
Updated: Sun, Oct 12
Updated: Sun, Oct 12
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Thermopylae Holdings Ltd
18.79%
Baker Bros. Advisors LP
9.21%
Capital World Investors
4.47%
Baillie Gifford & Co.
3.47%
Lecault (Veronique)
3.22%
Other
60.85%
Shareholders
Shareholders
Proportion
Thermopylae Holdings Ltd
18.79%
Baker Bros. Advisors LP
9.21%
Capital World Investors
4.47%
Baillie Gifford & Co.
3.47%
Lecault (Veronique)
3.22%
Other
60.85%
Shareholder Types
Shareholders
Proportion
Corporation
18.79%
Hedge Fund
16.22%
Investment Advisor
15.98%
Individual Investor
4.15%
Investment Advisor/Hedge Fund
2.97%
Bank and Trust
1.20%
Private Equity
1.13%
Research Firm
0.62%
Venture Capital
0.32%
Other
38.61%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
319
114.85M
38.43%
-43.37M
2025Q2
372
214.57M
71.89%
-123.81K
2025Q1
429
202.31M
67.85%
-22.54M
2024Q4
453
194.86M
65.41%
-21.40M
2024Q3
451
190.45M
64.55%
-29.37M
2024Q2
449
195.17M
66.27%
-23.48M
2024Q1
442
202.34M
69.21%
-22.49M
2023Q4
434
206.18M
71.07%
-38.61M
2023Q3
437
216.53M
74.89%
-39.50M
2023Q2
439
222.03M
76.83%
-29.38M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Thermopylae Holdings Ltd
56.14M
18.79%
--
--
Apr 01, 2025
Baker Bros. Advisors LP
27.53M
9.21%
--
--
Jun 30, 2025
Capital World Investors
13.36M
4.47%
--
--
Jun 30, 2025
Baillie Gifford & Co.
10.36M
3.47%
-835.83K
-7.47%
Jun 30, 2025
Lecault (Veronique)
9.61M
3.22%
--
--
Apr 01, 2025
Two Sigma Investments, LP
8.18M
2.74%
+2.41M
+41.75%
Jun 30, 2025
UBS Asset Management (Americas) LLC
5.00M
1.67%
-1.61M
-24.41%
Jun 30, 2025
ArrowMark Colorado Holdings, LLC
4.11M
1.37%
--
--
Jun 30, 2025
UBS Asset Management (Switzerland)
3.48M
1.16%
-5.59M
-61.65%
Jun 30, 2025
UBS Switzerland AG
3.43M
1.15%
-1.62M
-32.07%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Oct 2
Updated: Thu, Oct 2
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
2.11%
Virtus LifeSci Biotech Clinical Trials ETF
1.03%
ProShares Ultra Nasdaq Biotechnology
0.13%
Invesco Nasdaq Biotechnology ETF
0.13%
iShares Biotechnology ETF
0.09%
SPDR S&P International Small Cap ETF
0.08%
Invesco RAFI Developed Mkts ex-US SM ETF
0.03%
Avantis US Small Cap Equity ETF
0.01%
SPDR Portfolio Developed World ex-US ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion2.11%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.03%
ProShares Ultra Nasdaq Biotechnology
Proportion0.13%
Invesco Nasdaq Biotechnology ETF
Proportion0.13%
iShares Biotechnology ETF
Proportion0.09%
SPDR S&P International Small Cap ETF
Proportion0.08%
Invesco RAFI Developed Mkts ex-US SM ETF
Proportion0.03%
Avantis US Small Cap Equity ETF
Proportion0.01%
SPDR Portfolio Developed World ex-US ETF
Proportion0.01%
Fidelity Nasdaq Composite Index ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
